405 related articles for article (PubMed ID: 30553613)
1. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
Abufaraj M; Foerster B; Schernhammer E; Moschini M; Kimura S; Hassler MR; Preston MA; Karakiewicz PI; Remzi M; Shariat SF
Eur Urol; 2019 Apr; 75(4):649-658. PubMed ID: 30553613
[TBL] [Abstract][Full Text] [Related]
2. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Karakiewicz PI; Briganti A; Kimura S; Egawa S; Shariat SF
J Urol; 2020 Dec; 204(6):1129-1140. PubMed ID: 32716694
[TBL] [Abstract][Full Text] [Related]
4. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis.
Wang JK; Boorjian SA; Cheville JC; Kim SP; Tarrell RF; Thapa P; Frank I
World J Urol; 2012 Dec; 30(6):801-6. PubMed ID: 23132611
[TBL] [Abstract][Full Text] [Related]
5. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of cT1 micropapillary bladder cancer.
Willis DL; Fernandez MI; Dickstein RJ; Parikh S; Shah JB; Pisters LL; Guo CC; Henderson S; Czerniak BA; Grossman HB; Dinney CP; Kamat AM
J Urol; 2015 Apr; 193(4):1129-34. PubMed ID: 25254936
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
[TBL] [Abstract][Full Text] [Related]
8. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
[TBL] [Abstract][Full Text] [Related]
9. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
Magers MJ; Kaimakliotis HZ; Barboza MP; Bandali E; Adra N; Koch MO; Cheng L
J Clin Pathol; 2019 Aug; 72(8):550-553. PubMed ID: 31164444
[TBL] [Abstract][Full Text] [Related]
11. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
12. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.
Lonati C; Baumeister P; Afferi L; Mari A; Minervini A; Krajewski W; Azizi S; Hendricksen K; Martini A; Necchi A; Montorsi F; Briganti A; Colombo R; Tafuri A; Antonelli A; Cerruto MA; Rouprêt M; Masson-Lecomte A; Laukhtina E; D'Andrea D; Shariat SF; Soria F; Marra G; Gontero P; Contieri R; Hurle R; Valiquette AS; Mir MC; Zamboni S; Simeone C; Klatte T; Teoh JY; Yoshida S; Fujii Y; Carando R; Schulz GB; Mordasini L; Mattei A; Moschini M;
Eur Urol Focus; 2022 Sep; 8(5):1270-1277. PubMed ID: 34419381
[TBL] [Abstract][Full Text] [Related]
14. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
15. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
17. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
Tan WS; Grajales V; Contieri R; Hensley P; Bree K; Msaouel P; Guo CC; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
Eur Urol Open Sci; 2023 Jul; 53():16-22. PubMed ID: 37441349
[TBL] [Abstract][Full Text] [Related]
18. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.
Fairey AS; Daneshmand S; Wang L; Schuckman A; Lieskovsky G; Djaladat H; Cai J; Miranda G; Skinner EC
Urol Oncol; 2014 Feb; 32(2):110-6. PubMed ID: 23499168
[TBL] [Abstract][Full Text] [Related]
19. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
